Myrtelle’s rAAV-Olig001-ASPA Gene Therapy Candidate for Canavan Disease Receives Innovative Licensing and Access Pathway Designation from the UK Medicines and Healthcare Products Regulatory Agency
Wakefield, Mass., April 25th, 2023- Myrtelle Inc., (“Myrtelle” or the “Company”), a clinical stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
This article is featured on another website.
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]
Actym Therapeutics Expands Management Team with Key Appointments to Build Product Pipeline and Advance Clinical Development Strategies
Mary J. Janatpour, PhD, joins Actym as Chief Scientific Officer focused on expanding Actym’s pipeline Shouryadeep “Deep” Srivastava, MD, PhD, joins Actym as Senior Vice President of Clinical Development, leading Actym’s clinical activities BERKELEY, CA — June 25, 2024 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today the appointments of […]